Recipharm, Tillotts Pharma In Supply Pact
Recipharm, a contract development and manufacturing organization, has formed a long-term supply agreement with Tillotts Pharma, a Rheinfelden, Switzerland-based specialty pharmaceutical company, for technology transfer and commercial-scale development of Entocort (budesonide), a drug for treating mild-to-moderate active Crohn's disease in patients eight years and older and for maintenance of clinical remission of mild to moderate Crohn's disease for up to three months in adults, and Asacol (mesalamine) for treating moderately active ulcerative colitis in adults.
The partnership will also involve the commercial-scale development of Tillotts' ongoing development program for TP05, a drug for treating for acute ulcerative colitis. Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France; tablet and capsule manufacturing, including final packaging, from its facility in Fontaine, France; and bottle filling from its site in Lisbon, Portugal.
The total shared investment across the Recipharm network to enable this business amounts to EUR 3.5 million ($3.9 million), including investments to create new capacity as well as product-specific investments.